Aurinia Pharmaceuticals (AUPH) Tax Provisions (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Tax Provisions data on file, last reported at $9.6 million in Q1 2026.

• Quarterly Tax Provisions rose 852.24% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$164.5 million (down 8507.46% YoY) and the FY2025 annual result came in at -$173.0 million, down 10303.12% from the prior year.
• Tax Provisions improved to $9.6 million in Q1 2026, from -$175.1 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $9.6 million in Q1 2026 to a low of -$175.1 million in Q4 2025.
• A 5-year average of -$9.4 million and a median of $451000.0 in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2022 — Tax Provisions soared 11825.0% — and 2025, when it sank 57500.0%.
• Tracing AUPH's Tax Provisions over 5 years: stood at $827000.0 in 2022, then slumped by 45.47% to $451000.0 in 2023, then slumped by 167.41% to -$304000.0 in 2024, then slumped by 57500.0% to -$175.1 million in 2025, then jumped by 105.47% to $9.6 million in 2026.
• The last three Tax Provisions figures came in at $9.6 million (Q1 2026), -$175.1 million (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.